NeuroBo Pharmaceuticals, Inc. (NRBO)

Last Closing Price: 0.54 (2023-06-02)

Company Description

NeuroBo Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on novel treatments for neurodegenerative diseases. The company's novel lead candidate NB-01 is a drug candidate for diabetic neuropathic pain. NB-02 focuses on the treatment of neurodegenerative diseases. NeuroBo Pharmaceuticals Inc., formerly known as Gemphire Therapeutics Inc., is based in Northville, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-13.97M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.72
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -96.06%
Return on Assets (Trailing 12 Months) -66.28%
Current Ratio (Most Recent Fiscal Quarter) 2.87
Quick Ratio (Most Recent Fiscal Quarter) 2.87
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $0.86
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) $-5.43
Diluted Earnings per Share (Trailing 12 Months) $-15.51
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 27.24M
Free Float 27.03M
Market Capitalization $14.78M
Average Volume (Last 20 Days) 0.19M
Beta (Past 60 Months) -0.12
Percentage Held By Insiders (Latest Annual Proxy Report) 0.79%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%